Investigating the value of radiomics stemming from DSC quantitative biomarkers in IDH mutation prediction in gliomas.
IDH mutation
dynamic susceptibility contrast MRI
explainability
generalizability
gliomas
radiogenomics
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
06
2023
accepted:
31
10
2023
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
This study aims to assess the value of biomarker based radiomics to predict IDH mutation in gliomas. The patient cohort consists of 160 patients histopathologicaly proven of primary glioma (WHO grades 2-4) from 3 different centers. To quantify the DSC perfusion signal two different mathematical modeling methods were used (Gamma fitting, leakage correction algorithms) considering the assumptions about the compartments contributing in the blood flow between the extra- and intra vascular space. The Mean slope of increase (MSI) and the K The proposed framework on DSC-MRI radiogenomics in gliomas has the potential of becoming a reliable diagnostic support tool exploiting the mathematical modeling of the DSC signal to characterize IDH mutation status through a more reproducible and standardized signal analysis scheme for facilitating clinical translation.
Identifiants
pubmed: 38046592
doi: 10.3389/fneur.2023.1249452
pmc: PMC10690367
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1249452Informations de copyright
Copyright © 2023 Ioannidis, Pigott, Iv, Surlan-Popovic, Wintermark, Bisdas and Marias.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancers (Basel). 2019 Jan 18;11(1):
pubmed: 30669406
Neuroradiology. 2015 May;57(5):469-74
pubmed: 25614332
Radiology. 2008 Nov;249(2):601-13
pubmed: 18780827
Front Oncol. 2021 Mar 23;11:648528
pubmed: 33869047
Oncol Rep. 2019 Nov;42(5):2009-2015
pubmed: 31545461
Top Magn Reson Imaging. 2020 Apr;29(2):71-82
pubmed: 32271284
Ann Oncol. 2016 Apr;27(4):599-608
pubmed: 27005468
J Neurooncol. 1997 May;32(3):253-65
pubmed: 9049887
Neuro Oncol. 2014 Jan;16(1):81-91
pubmed: 24305719
Nat Med. 2012 Jan 26;18(4):624-9
pubmed: 22281806
Cancer Sci. 2012 Feb;103(2):269-73
pubmed: 22034964
Trends Cancer. 2021 Aug;7(8):666-667
pubmed: 34183306
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406550
Clin Cancer Res. 2017 Oct 15;23(20):6078-6085
pubmed: 28751449
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1479-86
pubmed: 15956519
Semin Ultrasound CT MR. 2022 Apr;43(2):153-169
pubmed: 35339256
Sci Rep. 2021 Jul 30;11(1):15546
pubmed: 34330946
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
Cancer Imaging. 2021 Mar 10;21(1):27
pubmed: 33691798
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150
pubmed: 28815663
Diagnostics (Basel). 2020 Apr 23;10(4):
pubmed: 32340318
J Clin Med. 2021 Apr 01;10(7):
pubmed: 33915813
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Radiology. 2010 Jan;254(1):200-9
pubmed: 20032153
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Bioengineering (Basel). 2023 Mar 23;10(4):
pubmed: 37106584
AJR Am J Roentgenol. 2011 Aug;197(2):468-73
pubmed: 21785096
Inf Fusion. 2022 Jun;82:99-122
pubmed: 35664012
J Appl Physiol. 1954 Jun;6(12):731-44
pubmed: 13174454
J Neurosci Rural Pract. 2019 Jan-Mar;10(1):78-84
pubmed: 30765975
Cancer Biol Med. 2021 Feb 15;18(1):272-282
pubmed: 33628600
Sci Rep. 2015 Nov 05;5:16238
pubmed: 26538165
Diagnostics (Basel). 2021 Jun 19;11(6):
pubmed: 34205442
J Cancer Res Clin Oncol. 2019 Mar;145(3):543-550
pubmed: 30719536
J Magn Reson Imaging. 2019 Mar;49(3):808-817
pubmed: 30194745
J Med Imaging (Bellingham). 2021 May;8(3):031905
pubmed: 33937440
Aging (Albany NY). 2019 Jan 29;11(2):673-696
pubmed: 30696801
Eur Radiol. 2021 Jul;31(7):5289-5299
pubmed: 33409784
World Neurosurg. 2019 May;125:e688-e696
pubmed: 30735871
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Neuro Oncol. 2021 Feb 25;23(2):304-313
pubmed: 32706862
J Clin Oncol. 2009 Sep 1;27(25):4150-4
pubmed: 19636000
BMC Med Inform Decis Mak. 2020 Jul 6;20(1):149
pubmed: 32631306
Sci Rep. 2018 Aug 6;8(1):11773
pubmed: 30082856
Phys Med. 2021 Mar;83:108-121
pubmed: 33765601
Radiology. 2013 May;267(2):543-50
pubmed: 23264345
Clin Cancer Res. 2018 Sep 15;24(18):4429-4436
pubmed: 29789422
Diagnostics (Basel). 2022 Feb 06;12(2):
pubmed: 35204514
Cancers (Basel). 2022 May 10;14(10):
pubmed: 35625967
AJNR Am J Neuroradiol. 2021 Jan;42(1):94-101
pubmed: 33243896
Lancet Oncol. 2014 Aug;15(9):e395-403
pubmed: 25079102
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
BMC Cancer. 2020 Jan 10;20(1):29
pubmed: 31924170
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
AJNR Am J Neuroradiol. 2009 Apr;30(4):662-8
pubmed: 19270105
J Magn Reson Imaging. 2021 May;53(5):1399-1407
pubmed: 33179832
Diagnostics (Basel). 2021 Dec 17;11(12):
pubmed: 34943617
Cancers (Basel). 2021 Aug 05;13(16):
pubmed: 34439118